Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer

Clinical and Translational Oncology

Volumn 13, Issue 10, 2011, Pages 710-714

  Koukourakis, Georgios V ^a   Sotiropoulou Lontou, Anastasia ^a  

^a UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Avastin; Bevacizumab; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN A; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC THERAPY; BINDING AFFINITY; BINDING SITE; CASTRATION RESISTANT PROSTATE CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81255142967     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0720-z     Document Type: Review

References (31)

1. Ries LAG, Melbert D (2008) SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. SEER, Bethesda, MD. http://seer.cancer.gov/csr/1975- 2005/, based on November 2007 SEER data submission, posted to the SEER website
2. Cancer.net. Colorectal cancer: overview. Available at http://www.cancer.net/patient/Cancer+Types/Colorectal+Cancer
3. I.J. Fidler L.M. Ellis 1994 The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 185 188 7525076 10.1016/0092-8674(94)90187-2 1:CAS:528:DyaK2cXmslOltLY%3D (Pubitemid 24324908)
4. J. Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
5. N. Ferrara H.P. Gerber J. LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 12778165 10.1038/nm0603-669 1:CAS:528: DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
6. H.F. Dvorak 2006 Discovery of vascular permeability factor (VPF) Exp Cell Res 312 522 526 16430882 10.1016/j.yexcr.2005.11.026 1:CAS:528: DC%2BD28XhvVWltb8%3D (Pubitemid 43290329)
7. J.A. Nagy E. Vasile D. Feng, et al. 2002 VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations Cold Spring Harb Symp Quant Biol 67 227 237 12858545 10.1101/sqb.2002.67.227 1:CAS:528: DC%2BD3sXltlGgs7g%3D (Pubitemid 36775516)
8. K. Tanaka S. Yamaguchi A. Sawano M. Shibuya 1997 Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase) Jpn J Cancer Res 88 867 876 9369935 10.1111/j.1349-7006.1997. tb00463.x 1:CAS:528:DyaK2sXms12hur4%3D (Pubitemid 27475089)
9. L. Wang H. Zeng P. Wang, et al. 2003 Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration J Biol Chem 278 48848 48860 14514674 10.1074/jbc.M310047200 1:CAS:528:DC%2BD3sXptlGkurw%3D
10. K. Zafirellis G. Agrogiannis A. Zachaki, et al. 2008 Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer J Surg Res 147 99 107 17655863 10.1016/j.jss.2007.05.041 1:CAS:528:DC%2BD1cXlslaiu7Y%3D (Pubitemid 351626074)
11. Y. Takebayashi S. Aklyama K. Yamada, et al. 1996 Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma Cancer 78 226 231 8673996 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J 1:STN:280:DyaK283osVartQ%3D%3D (Pubitemid 26234563)
12. O. Melnyk M.A. Shuman K.J. Kim 1996 Vascular endothelial growth factor promotes tumour dissemination by a mechanism distinct from its effect on primary tumour growth Cancer Res 56 921 924 8631034 1:CAS:528:DyaK28XhtVCltrc%3D (Pubitemid 26055486)
13. K.J. Kim B. Li J. Winer, et al. 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 841 844 7683111 10.1038/362841a0 1:CAS:528:DyaK3sXktVKju7s%3D (Pubitemid 23132159)
14. R.S. Warren H. Yuan M.R. Matli, et al. 1995 Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis J Clin Invest 95 1789 1797 7535799 10.1172/JCI117857 1:CAS:528:DyaK2MXkslyktb4%3D
15. G. Klement S. Baruchel J. Rak, et al. 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity J Clin Invest 105 R15 24 10772661 10.1172/JCI8829 1:CAS:528:DC%2BD3cXisFOlurc%3D
16. J.L. Rubenstein J. Kim T. Ozawa, et al. 2000 Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2 306 314 11005565 10.1038/sj.neo.7900102 1:CAS:528: DC%2BD3cXntVCjtb8%3D
17. C. Calabrese H. Poppleton M. Kocak, et al. 2007 A perivascular niche for brain tumor stem cells Cancer Cell 11 69 82 17222791 10.1016/j.ccr.2006.11.020 1:CAS:528:DC%2BD2sXhtFClsLY%3D (Pubitemid 46054518)
18. K. Margolin M.S. Gordon E. Holmgren, et al. 2001 Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J Clin Oncol 19 851 856 11157039 1:CAS:528:DC%2BD3MXhtlGrt7Y%3D (Pubitemid 32119101)
19. M.A. Cobleigh V.K. Langmuir G.W. Sledge, et al. 2003 A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 [5Suppl16] 117 124 14613032 10.1053/j.seminoncol.2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF (Pubitemid 37433402)
20. J.C. Yang L. Haworth R.M. Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 12890841 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D (Pubitemid 36910021)
21. M.S. Gordon K. Margolin M. Talpaz, et al. 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850 11157038 1:CAS:528:DC%2BD3MXhtlGrt7k%3D (Pubitemid 32119100)
22. R.K. Jain 2001 Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
23. H. Hurwitz L. Fehrenbacher W. Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
24. H.I. Hurwitz L. Fehrenbacher J.D. Hainsworth, et al. 2005 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 3502 3508 15908660 10.1200/JCO.2005.10.017 1:CAS:528:DC%2BD2MXlsVyhsrs%3D
25. Avastin prescribing information. Available at http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf. Accessed 20 July 2006
26. C.S. Fuchs J. Marshal E. Mitchell, et al. 2007 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study J Clin Oncol 25 4779 4786 17947725 10.1200/JCO.2007.11.3357 1:CAS:528:DC%2BD2sXhtlCgsLbM (Pubitemid 350086481)
27. C.S. Fuchs J. Marshall J. Barrueco 2008 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 689 690 18235136 10.1200/JCO.2007.15.5390 (Pubitemid 351264373)
28. L.B. Saltz S. Clarke E. Díaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
29. C.H. Köhne J. De Greve J.T. Hartmann, et al. 2008 Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer EORTC study 40015. Ann Oncol 19 920 926 10.1093/annonc/mdm544 (Pubitemid 351627308)
30. N. Ziras A. Polyzos S. Kakolyris 2008 CAPIRI (capecitabine, irinotecan)+bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan)+bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): interim analysis for safety of a randomized phase III trial J Clin Oncol 26 [Suppl20] 15008
31. A. Grothey M. Sugrue E. Hedrick 2007 Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) J Clin Oncol 25 [Suppl18] 4036